表紙
市場調查報告書

全球藥物研發市場:各醫藥品類型,技術,服務,終端用戶,地區 - 成長,趨勢,預測(2018年∼2023年)

Drug Discovery Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 613017
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
全球藥物研發市場:各醫藥品類型,技術,服務,終端用戶,地區 - 成長,趨勢,預測(2018年∼2023年) Drug Discovery Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 115 Pages
簡介

全球藥物研發市場,預計從2018年到2023年的調查期間中,以約8%的年複合成長率發展。各地區中,由於對市場有利的政府法規和技術開發使北美最大成為市場。

本報告提供全球藥物研發市場相關調查,市場概要,各醫藥品類型、技術、服務、終端用戶、地區的市場趨勢,市場規模的變化與預測,市場佔有率,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要市場影響因素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 多樣的疾病的罹患率的上升
    • 技術進步與創新
    • 醫療支出的增加
    • 重量級醫藥品的專利到期
  • 市場阻礙因素
    • 報酬率低的巨大的設備投資
    • 嚴格的政府法規
  • 市場機會
  • 課題

第7章 全球藥物研發市場:市場區隔

  • 各醫藥品類型
    • 低分子醫藥品
    • 生物醫藥品
  • 各技術
    • 高通量篩檢(HTS)
    • 生物晶片
    • 生物資訊學(生命資訊科學)
    • 藥理基因學、藥物遺傳學
    • 組合化學
    • 奈米技術
    • 光譜學
    • 代謝體學
    • 其他
  • 各類服務
    • 藥物代謝及藥物動力學(DMPK)服務
    • 醫藥品服務
    • 化學的服務
    • 生物學的服務
  • 各終端用戶
    • 研究機關
    • 製藥企業
    • 生物科技企業
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,聯盟
  • 新產品的銷售

第9章 主要企業的簡介

  • Pfizer Inc
  • Glaxosmithkline Llc
  • Merck & Co. Inc
  • Agilent Technologies Inc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Bayer Ag
  • Abbott Laboratories Inc
  • Astrazeneca Plc
  • 島津製作所
  • 其他企業

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 48320

The propelling factors for the growth of the drug discovery market include the rising prevalence of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and upcoming patent expiration of blockbuster drugs.

The diverse range of diseases, primarily cardiovascular disease, infectious diseases, diabetes, and kidney-related complications, has a high prevalence, globally. Thus, the increasing prevalence of a diverse range of diseases among all age groups and its burden, globally, drives the demand for drug discovery and its market.

There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. Due to automation, multi-detector readers, imaging hardware and software, high-throughput screening is one of the most widely used drug discovery technologies.

In recent years, there has been a rising demand for speciality medicines that are expected to ultimately influence the small molecule drug discovery market in a positive manner, as most of the speciality medicines are small molecules.

The gradual rise in the healthcare expenditure regionally helps the new pharmaceutical technology advancement. Although with high expenditure, there is a need for redirecting the resources, the transition toward better usability of healthcare expenditure for drug development is under progress.

Key Market Trends

Biologics Drug is the Segment that is Expected to Grow Fastest under Drug Type

A biologic drug is a product that is produced from living organisms or contains components of living organisms. Biologic drugs include a wide variety of products derived from human, animal, or microorganisms. Biologic drugs are used for the treatment of numerous diseases and conditions and are the most advanced therapies available. Biologic treatments are for autoimmune diseases, which include the treatments for rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, and a range of related disorders, and have continued to see increasing usage across geographies. Biologic drugs are expected to be fueled by innovations in oncology, autoimmune, and diabetes treatments.

The increasing applications of small molecule drugs for the treatment of chronic diseases are leading to the increased demand for these drugs in the market. Thus, due to the aforementioned factors, small molecule drugs dominate the biologics in the current healthcare market.

Asia-Pacific is Expected to Increase with the Fastest Growth Over the Forecast Period

The Asia Pacific is the fastest-growing region, due to the presence of skilled labor at an affordable cost, the rise in disposable income, and favorable government policies. There has also been phenomenal growth in the outsourcing companies in the Chinese region, over the last decade, which has complemented the restructuring of the R&D that has taken place. Thus, owing to the large deals of pharmaceutical companies and more number of research being done, the market for drug discovery is expected to grow.

Competitive Landscape

The market studied has various pharmaceutical companies that are investing billions of dollars in artificial intelligence (AI), in order to make the drug discovery process significantly faster and cost-efficient. The pharmaceutical and biotech companies are increasing their collaborations with contract development and manufacturing organizations; thus, playing a crucial role in the development and innovation of new drugs.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Various Chronic Diseases
    • 4.2.2 Increasing Research and Development Investments for Development of Novel Drug Molecules
    • 4.2.3 Increasing Healthcare Expenditure
  • 4.3 Market Restraints
    • 4.3.1 Huge Capital Investment with Low Profit Margins
    • 4.3.2 Stringent Government Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 Small Molecule Drugs
    • 5.1.2 Biologic Drugs
  • 5.2 By Technology
    • 5.2.1 High Throughput Screening
    • 5.2.2 Pharmacogenomics
    • 5.2.3 Combinatorial Chemistry
    • 5.2.4 Nanotechnology
    • 5.2.5 Other Technologies
  • 5.3 By End User
    • 5.3.1 Pharmaceutical Companies
    • 5.3.2 Contract Research Organizations(CROs)
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 United Kingdom
      • 5.4.2.2 Germany
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer Inc.
    • 6.1.2 GlaxoSmithKline PLC
    • 6.1.3 Merck & Co. Inc.
    • 6.1.4 Agilent Technologies Inc.
    • 6.1.5 Eli Lilly and Company
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 Bayer AG
    • 6.1.8 Abbott Laboratories Inc.
    • 6.1.9 AstraZeneca PLC
    • 6.1.10 Shimadzu Corp.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS